Intervention Review

You have free access to this content

Mitoxantrone for multiple sclerosis

  1. Filippo Martinelli Boneschi1,*,
  2. Laura Vacchi2,
  3. Marco Rovaris3,
  4. Ruggero Capra4,
  5. Giancarlo Comi5

Editorial Group: Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group

Published Online: 31 MAY 2013

Assessed as up-to-date: 30 AUG 2012

DOI: 10.1002/14651858.CD002127.pub3


How to Cite

Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD002127. DOI: 10.1002/14651858.CD002127.pub3.

Author Information

  1. 1

    INSPE - San Raffaele Scientific Institute, Department of Neurology, Milano, Italy

  2. 2

    Scientific Institute and University Ospedale San Raffaele, Institute of Experimental Neurology (INSPE), Milano, Italy

  3. 3

    I.R.C.S.S. S. Maria Nascente - Fondazione Don Gnocchi, U.O. Sclerosi Multipla, Milano, Italy

  4. 4

    Spedali Civili, Brescia, Italy

  5. 5

    San Raffaele Hospital, Department of Neurology, Milano, Italy

*Filippo Martinelli Boneschi, Department of Neurology, INSPE - San Raffaele Scientific Institute, Via Olgettina, 48, Milano, 20131, Italy. filippo.martinelli@hsr.it.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 31 MAY 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Edan 1997 {published data only}
  • Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. Journal of Neurology, Neurosurgery, and Psychiatry 1997;62(2):112-8.
Hartung 2002 {published data only}
  • Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360(9350):2018-25.
  • Hartung HP, Gonsette R, the MIMSSG. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomized, observer-blind phase III trial: clinical results and three-year follow-up. Neurology 1999;52 Suppl 2:A290 (S45.005).
  • Krapf H, Morrissey SP, Zenker O, Zwingers T, Gonsette R, Hartung HP, et al. Mitoxantrone in progressive multiple sclerosis: MRI results of the european phase III trial. Neurology 1999;52 Suppl 2:A495 (P06.044).
  • Krapf H, Morrissey SP, Zenker O, Zwingers T, Gonsette R, Hartung HP, Group MIMS Study. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 2005;65(5):690-5.
  • Nadeau SE. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology 2006;66:1457-8.
Millefiorini 1997 {published data only}
  • Bastianello S, Pozzilli C, D'Andrea F, Millefiorini E, Trojano M, Morino S, et al. A controlled trial of mitoxantrone in multiple sclerosis: Serial MRI evaluation at one year. The Canadian Journal of Neurological Sciences 1994;21(3):266-70.
  • Millefiorini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. Journal of Neurology 1997;244:153-9. [MEDLINE: 9050955]

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Capra 1993 {published data only}
  • Capra R, Marciano N. Mitoxantrone therapy of secondary progressive multiple sclerosis: pilot study. Neurology 1993;43(4 Suppl 2):A281.
Edan 2001 {published data only}
  • Edan G, Le Page E, Taurin G, Le Duff F, Kerdoncuff V, De Marco O, et al. Safety profile of mitoxantrone in a cohort of 293 multiple sclerosis patients. Neurology 2001;56 Suppl 3:A149.
Edan 2011 {published data only}
  • Edan G, Comi G, Le Page E, Leray E, Rocca MA, Filippi M. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. Journal of Neurology, Neurosurgery, and Psychiatry 2011;82:1344-50.
Gonsette 1990 {published data only}
  • Gonsette RE, Demonty L. Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology 1990;40 Suppl 1:537.
Goodkin 2001 {published data only}
  • Goodkin DE. Registry to evaluate Novantrone effects in worsening MS (the RENEW study): a work in progress. Multiple Sclerosis 2001;7 Suppl 1:129.
Hamzehloo 2007 {published data only}
Kappos 1990 {published data only}
  • Kappos L, Gold R, Kunstler E, Rohrbach E, Heun R, Stadt D, et al. Mitoxantrone in the treatment of rapidly progressive MS: a pilot study with serial gadolinium (Gd)-enhanced MRI. Neurology 1990;40 Suppl 1:261.
Kornhuber 1992 {published data only}
Krapf 1995 {published data only}
  • Krapf H, Mauch E, Fetzer U, Laufen H, Kornhuber HH. Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology 1995;37(2):113-9.
Mauch 1999 {published data only}
  • Mauch E, et al. Mitoxantrone in the treatment of patients with multiple sclerosis (MS): a large single-center experience. Multiple Sclerosis 1999;5 Suppl 1:94.
Noseworthy 1993 {published data only}
Rees 1998 {published data only}
  • Reess J, et al. Results of an open study with 75 MS patients treated with mitoxantrone. 14th Congress of the European Committee for treatment and research in multiple sclerosis - Multiple Sclerosis. 1998, issue 4:382.
Van de Wyngaert 2001 {published data only}
  • Van de Wyngaert FA, Beguin C, D'Hooghe MB, Dooms G, Lissoir F, Carton H, et al. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurologica Belgica 2001;101(4):210-6.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Avasarala 2003
  • Avasarala JR, Cross AH, Clifford DB, Singer BA, Siegel BA, Abbey EE. Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Multiple Sclerosis 2003;9(1):59-62.
Benjamin 1985
Bernitsas 2006
Brassat 2002
  • Brassat D, Recher C, Waubant E, Le Page E, Rigal-Huguet F, Laurent G, et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002;59(6):954-5.
Cattaneo 2003
Cavaletti 2004
  • Cavaletti G, Cavaletti E, Crippa L, Di Luccio E, Oggioni N, Lolli F, et al. Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis. Journal of Neuroimmunology 2004;151:55-65.
Compston 1998
  • Compston AMW, Lassmann H, Ebers G, Wekerle H. McAlpine's Multiple Sclerosis. Churchill Livingstone, New York, 1998.
De Castro 1995
Debouverie 2004
  • Debouverie M, Vandenberghe N, Morrissey SP, Anxionnat R, Vespignani H, Edan G, et al. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis. Multiple Sclerosis 2004;10:407-12.
Delisse 2004
  • Delisse B, De Seze J, Mackowiak A, N' Kendjuo JB, Verier A, Derepeer O, et al. Therapy related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis. Multiple Sclerosis 2004;10:92.
DerSimonian 1986
Durr 1983
Edan 2001 b
  • Edan G, Brochet B, Clanet M, et al. Safety profile of mitoxantrone in a cohort of 800 multiple sclerosis patients. Multiple Sclerosis 2001;7:S14.
Ehninger 1986
FDA 1999
  • U.S. Food, Drug Administration. FDA safety review. NDA 21-120, Novantrone. http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3582b1c.pdf (accessed February 2013).
FDA 2012
  • U.S. Food, Drug Administration. FDA Medication Guide. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM297876.pdf (accessed February 2013).
FDA 2012b
  • U.S. Food, Drug Administration. FDA Medication Guide. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019297s035lbl.pdf (accessed February 2013).
Felix 1998
Fidler 1985
  • Fidler JM, Smith F, Gibbons J. Mitoxantrone inhibits helper function and enhances suppressor activity. Agents and Actions 1985;16:607-8.
Fidler 1986a
  • Fidler JM, DeJoy SQ, Gibbons JJ, Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. Journal of Immunology 1986;137(2):727-32.
Fidler 1986b
  • Fidler JM, DeJoy SQ, Smith FR 3rd, Gibbons JJ Jr. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone- treated mice. Journal of Immunology 1986;136(8):2747-54.
Filippi 1998
Filippi 2001
Filippini 2003
Ghalie 2002a
  • Ghalie RG, Mauch E, Edan G, Hartung HP, Gonsette RE, Eisenmann S, et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Multiple Sclerosis 2002;8(5):441-5.
Ghalie 2002b
Goffette 2005
  • Goffette S, Van Pesch V, Vanoverschelde JL, Morandini E, Sindic CJ. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. Journal of Neurology 2005;252(10):1217-22.
Gonsette 2003
Gonsette 2004
Goodkin 1992
  • Goodkin DE, Cookfair D, Wende K, Bourdette D, Pullicino P, Scherokman B, et al. Inter- and intra-rater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Neurology 1992;42:859-63.
Goodkin 2003
Heesen 2003
  • Heesen C, Bruegmann M, Gbdamosi J, Koch E, Monch A, Buhmann C. Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Multiple Sclerosis 2003;9(2):213-4.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011:Available from www.cochrane-handbook.org.
Kieseier 2011
Krapcho 1994
  • Krapcho AP, Petry ME, Getahun Z, Landi JJ Jr, Stallman J, Polsenberg JF, et al. 6,9-bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations. Journal of Medicinal Chemistry 1994;37(6):828-37.
Kurtzke 1983
La Mantia 2010
Levine 1986
Lublin 1987
  • Lublin FD, Lavasa M, Viti C, Knobler RL. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clinical Immunology and Immunopathology 1987;45(1):122-8.
Lublin 1996
  • Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46(4):907-11.
Marriott 2010
  • Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;74(18):1463-70.
Martinelli 2011
  • Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 2011;77(21):1887-95.
McDonald 2001
Mikol 2001
  • Mikol DDBE. Novantrone plus dexrazoxane therapy in multiple sclerosis patients: a safety and tolerability pilot study. Multiple Sclerosis 2001;7 Suppl 1:14.
Miller 1991
  • Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. Journal of Neurology, Neurosurgery, and Psychiatry 1991;54(8):683-8.
Mistry 2005
  • Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. New England Journal of Medicine 2005;352(15):1529-38.
Mustafa 1993
  • Mustafa M, Diener P, Sun JB, Link H, Olsson T. Immunopharmacologic modulation of experimental allergic encephalomyelitis: low-dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cell-mediated myelin-directed autoimmunity. Scandinavian Journal of Immunology 1993;38(6):499-507.
Olindo 2002
Polman 2005
Polman 2011
Poser 1983
Quesnel 1993
  • Quesnel B, Kantarjian H, Pedersen-Bjergaard J, Brault P, Estey E, Harousseau JL, et al. Therapy-related acute myeloid leukemia with t (8;21), inv (16) and t (8;16): A report on 25 cases and review of the literature. Journal of Clinical Oncology 1993;11:2370-9.
Radu 2002
  • Radu TD, Marc D, Herve V. Acute myeloid leukaemia (AML) induced by mitoxantrone. Multiple Sclerosis 2002;8:342 (S127).
Ramey 1992
  • Ramey DR, Reynauld JP, Fries JF. The health assessment questionnaire. Arthritis Care Research 1992;5:119–29.
Review Manager 2013 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2013.
Rice 2001
  • Rice GP, Incorvaia B, Munari L, Ebers G, Polman C, D'Amico R, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD002002]
Rivera 2008
  • Rivera V, Al-Sabbagh A, Bennett R, et al. RENEW study update XVIII: Ongoing evaluation of the safety and tolerability of mitoxantrone in worsening multiple sclerosis. Multiple Sclerosis 2008;14 Suppl 1:175.
Sibley 1996
  • Sibley W. A guide to treatments. 4th edition. New York: Demos Vermande, 1996.
Smith 1983
Stewart 1986
  • Stewart DJ, Green RM, Mikhael NZ, Montpetit V, Thibault M, Marcoun JA. Human autopsy tissue concentrations of mitoxantrone. Cancer Treatment Reports 1986;70:1255-61.
Thompson 2010
  • Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurology 2010;9(12):1182-99.
Vicari 1998
  • Vicari AM, Ciceri F, Folli F, Lanzi R, Colombo B, Comi G, et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 1998;12(3):441-2.
Voltz 2004
  • Voltz R, Starck M, Zingler V, Strupp M, Kolb HJ. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Multiple Sclerosis 2004;10:472-4.
Watson 1991
Weinshenker 1989
  • Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112 Pt 1:133-46.
Weiss 1999
Yusuf 1985
  • Yusuf SPR, Lewis J, Collins R, Sleight P. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases 1985;27(5):335-71.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Martinelli Boneschi 2013